Generic Name and Formulations:
Insulin lispro 100 Units/mL; soln for SC inj or continuous subcutaneous insulin infusion pump, or IV inj; contains zinc, m-cresol.
RECENT UPDATESMonograph added.
Indications for ADMELOG:
Type 1 diabetes mellitus in adults and children. Type 2 diabetes mellitus in adults.
Adults and Children:
<3yrs: not established. ≥3yrs: Individualize. For SC inj: give within 15mins before a meal or immediately after a meal; use with intermediate or long-acting insulin. Rotate inj sites (abdomen, thigh, upper arm, buttocks). For continuous SC infusion pump: administer into abdominal wall; do not dilute or mix Admelog; change Admelog in the reservoir at least every 7 days, change the infusion sets and insertion site at least every 3 days. For IV inj: dilute Admelog; give only under medical supervision; closely monitor blood glucose and potassium.
During episodes of hypoglycemia.
Do not share pens between patients, or needles and syringes when using vials. Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Increased risk of hypo- or hyperglycemia if changes in physical activity, meal patterns, concomitant medications, renal or hepatic function, insulin regimen and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Hyperglycemia and ketoacidosis due to insulin pump device malfunction: see full labeling. Renal or hepatic impairment. Pregnancy. Nursing mothers.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (eg, octreotide), sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, phenothiazines, sympathomimetics, somatropin, thyroid hormones, oral contraceptives, estrogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia. Do not mix with any other insulin.
Hypoglycemia, allergic reactions, inj site reactions, lipodystrophy, pruritus, rash, hypokalemia, weight gain, peripheral edema; hypersensitivity reactions.
Multi-dose vials (10mL)—1; SoloStar prefilled pen (3mL)—5
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- #MeToo: Helping Victims Cope With Sexual Harassment
- Association Between Psychosis and Development of Dementia in Older Men
- Phonemic Verbal Advantage in Mild Cognitive Impairment May Predict Risk for Alzheimer Disease
- Psychosis Could Be a Potential Side Effect of Steroid Treatment in Kids
- Guidance Offered for Improving Mental Health in Workplace
- Triiodothyronine in the Treatment of Bipolar Depression
- Nutritional Influences on Bipolar Disorder in Children
- Old Challenges and New Directions in Managing Tardive Dyskinesia
- Early Intervention Strategies for Bipolar Disorder: Clinical Dilemmas and Directions
- Similar Rates of Childhood Trauma in Schizophrenia and Substance Use Disorders
- Bully for Us: Confronting Medicine's Bullying Problem
- Personality Functioning Associated With Global Functioning in Bipolar Disorder I
- Higher Incidence of Mania in Adults With Intellectual Disabilities vs General Population
- Youth With Gender Nonconformity Vulnerable to Adversity
- Negative Affect That Lingers Tied to Health 10 Years Later